Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Allergy Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Allergy Other
    FDA Approves a C1-Esterase Inhibitor for Abdominal Attacks, Facial Swelling Associated With HAE - (DGNews)
    FDA Approves Bepotastine Besilate Solution for Ocular Itching Associated With Allergies - (DGNews)
    FDA Approves Levocetirizine Dihydrochloride for Paediatric Nasal Allergies - (DGNews)
    Milk is Safe, Encouraged, for Some Children After Treatment for Milk Allergy - (DGNews)
    Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis - (BMJ)

    News archive

     Recent webcasts/CME - Allergy Other
    • Alpha1-Antitrypsin Deficiency: Incidence, Screening, and Management
    • Early Detection of Alpha1-Antitrypsin (AAT) Deficiency Helps Prevent Disease Progression
    • Advances in Hereditary Angioedema Treatment: Considerations, Criteria & the New Therapy Options for Treatment & Prevention of HAE Attacks
      Sublingual Immunotherapy (SLIT) for Allergic Rhinitis The Latest Evidence
      Update in Hereditary Angioedema: A Disease in Rapid Evolution

      Webcasts/CME archive

       Recent cases - Allergy Other
        Gallbladder Edema in Type 1 Diabetic Patient due to Delayed-type Insulin Allergy
        Anaphylaxis Following Intravenous Fluorescein Angiography in a Vitreoretinal Clinic: Report of 4 Cases
        Acute Allergic Reaction due to Milk Proteins Contaminating Lactose Added to Corticosteroid for Injection
        Acute Generalized Exanthematous Pustulosis (AGEP) Triggered by a Spider Bite
        Anaphylactic Reaction to Camomile Tea

        Cases archive
          




        my personal edition > allergy other > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        Allegra-D 24 Hour (fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg) Extended Release Tablets Now Available for Seasonal Allergy Sufferers

        Once-daily formulation provides 24-hour relief of seasonal allergy symptoms with nasal congestion

        BRIDGEWATER, NJ -- July 28 -- Sanofi-aventis announced today that Allegra-D(R) 24 Hour (fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg) Extended-Release Tablets are now available for the treatment of seasonal allergy symptoms with nasal congestion in adults and children 12 years of age and older.

        Allegra-D 24 Hour provides allergy patients with the power of once-daily Allegra (fexofenadine HCl) 180 mg, combined with 24-hour relief from nasal congestion, in a convenient, once- daily tablet. Allegra-D 24 Hour is an addition to the Allegra(R) family of non-sedating and non-impairing products available for the treatment of seasonal allergy symptoms.

        More than 40 million adults and children in the United States suffer from seasonal allergies and associated symptoms, such as nasal congestion, watery eyes, runny nose, sneezing and itchy throat.

        In fact, 9 out of 10 allergy patients experience congestion and consider it the most frustrating symptom. These symptoms are caused by the body's reaction to allergens and typically occur in the spring and fall when large amounts of allergens, such as pollen, are in the air.

        Allegra-D 24 Hour utilizes a controlled-release technology that provides a smooth delivery of pseudoephedrine over the entire dosing period, providing 24-hour nasal congestion relief in a convenient once-a-day dosage.

        About Allegra Line of Products
        Allegra offers an extensive family of products to provide patients with greater convenience and flexibility in treating their different seasonal allergy needs (Allegra 30 mg and 60 mg twice daily, Allegra 180 mg once daily, Allegra-D 12 Hour (fexofenadine HCl 60 mg/ pseudoephedrine HCl 120 mg) Extended-Release Tablets [for twice daily dosing] and Allegra-D 24 Hour).

        The side effects with Allegra 180 mg for seasonal allergies are low and may include headache, cold or back pain. The side effects for Allegra 60 mg for seasonal allergies are low; less than 3% of people experience cold or flu, nausea, menstrual pain or drowsiness. The side effects for Allegra 30 mg are low and may include headache, cold, coughing or accidental injury.

        Side effects with Allegra-D 12 Hour and Allegra-D 24 Hour were similar to Allegra 60 mg alone (headache, insomnia or nausea) and Allegra 180 mg alone (headache, cold or backache) respectively.

        Due to the decongestant (pseudoephedrine) component in both Allegra-D 12 Hour and Allegra-D 24 Hour, these products must not be used if you: are taking an MAO inhibitor (a medication for depression) or have stopped taking an MAO inhibitor within 14 days; retain urine; have narrow-angle glaucoma; have severe high blood pressure or severe heart disease.

        Side effects with pseudoephedrine may include nervousness, restlessness, dizziness, or insomnia. Headache, drowsiness, increased heart rate, palpitations, increased blood pressure, and abnormal heart rhythms have been reported. You should also tell your doctor if you have high blood pressure, diabetes, heart disease, glaucoma, thyroid disease, impaired kidney function, or symptoms of an enlarged prostate such as difficulty urinating.


        SOURCE: Sanofi-aventis Group



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send